Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973466 | 0.90 | NPC1 (0.44) | NPC1RAB9AMAPTSMN1; SMN2GRM4 | |
| SCHEMBL21189264 | 0.90 | NPC1 (0.44) | NPC1RAB9AMAPTSMN1; SMN2GRM4 | |
| SCHEMBL21189330 | 0.90 | NPC1 (0.44) | NPC1RAB9AMAPTSMN1; SMN2GRM4 | |
| SCHEMBL21189367 | 0.86 | RAB9A (0.44) | NPC1RAB9AMAPTSMN1; SMN2GRM4 | |
| SCHEMBL21189208 | 0.86 | NPC1 (0.42) | NPC1RAB9AMAPTSMN1; SMN2GRM4 | |
| SCHEMBL21189259 | 0.83 | NPC1 (0.46) | NPC1RAB9AMAPTSMN1; SMN2GRM4 | |
| SCHEMBL21189349 | 0.83 | NPC1 (0.44) | NPC1RAB9AMAPTSMN1; SMN2GRM4 | |
| SCHEMBL21189289 | 0.83 | NPC1 (0.46) | NPC1RAB9AMAPTSMN1; SMN2GRM4 | |
| SCHEMBL21189358 | 0.83 | MAOB (0.39) | NPC1RAB9AMAPTSMN1; SMN2LMNA | |
| SCHEMBL21189408 | 0.82 | NPC1 (0.42) | NPC1RAB9AMAPTSMN1; SMN2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | NPC1 983/4885RAB9A 1393/4885MAPT 3165/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | NPC1 983/4885RAB9A 1393/4885MAPT 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.